Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Merck
Medtronic
Boehringer Ingelheim
Colorcon

Last Updated: May 21, 2022

CLINICAL TRIALS PROFILE FOR DUVELISIB


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Duvelisib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01476657 ↗ A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies Terminated Infinity Pharmaceuticals, Inc. Phase 1 2011-10-01 The purpose of this study is to determine the safety, maximum tolerated dose and pharmacokinetics of IPI-145 in patients with advanced hematologic malignancies.
NCT01476657 ↗ A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies Terminated SecuraBio Phase 1 2011-10-01 The purpose of this study is to determine the safety, maximum tolerated dose and pharmacokinetics of IPI-145 in patients with advanced hematologic malignancies.
NCT01653756 ↗ A Phase 2a, Efficacy and Safety Study of Duvelisib in Mild Asthmatic Subjects Completed Infinity Pharmaceuticals, Inc. Phase 2 2012-07-01 The purpose of this study is to examine the effects of multi-dose regimens of IPI-145 on lung function in mild asthmatic subjects following allergen challenge.
NCT01653756 ↗ A Phase 2a, Efficacy and Safety Study of Duvelisib in Mild Asthmatic Subjects Completed SecuraBio Phase 2 2012-07-01 The purpose of this study is to examine the effects of multi-dose regimens of IPI-145 on lung function in mild asthmatic subjects following allergen challenge.
NCT01851707 ↗ A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone Completed Infinity Pharmaceuticals, Inc. Phase 2 2013-04-01 The purpose of this study is to investigate the safety and efficacy of multiple dose levels of the investigational product (study drug), IPI-145, in combination with methotrexate compared to methotrexate alone in subjects with active moderate-to-severe Rheumatoid Arthritis.
NCT01851707 ↗ A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone Completed SecuraBio Phase 2 2013-04-01 The purpose of this study is to investigate the safety and efficacy of multiple dose levels of the investigational product (study drug), IPI-145, in combination with methotrexate compared to methotrexate alone in subjects with active moderate-to-severe Rheumatoid Arthritis.
NCT01871675 ↗ Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies Completed Infinity Pharmaceuticals, Inc. Phase 1 2013-05-01 The goal of this study is to characterize the safety, maximum tolerated dose (MTD) and preliminary efficacy profile of IPI-145 given in combination with rituximab, or bendamustine plus rituximab, to subjects with select relapsed/refractory hematologic malignancies.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Duvelisib

Condition Name

Condition Name for Duvelisib
Intervention Trials
Chronic Lymphocytic Leukemia 7
Small Lymphocytic Lymphoma 6
Lymphoma 4
Non-hodgkin Lymphoma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Duvelisib
Intervention Trials
Lymphoma 24
Leukemia, Lymphocytic, Chronic, B-Cell 11
Leukemia, Lymphoid 10
Leukemia 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Duvelisib

Trials by Country

Trials by Country for Duvelisib
Location Trials
United States 141
Italy 9
Mexico 8
United Kingdom 7
Germany 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Duvelisib
Location Trials
Missouri 11
Massachusetts 11
Florida 11
New York 11
California 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Duvelisib

Clinical Trial Phase

Clinical Trial Phase for Duvelisib
Clinical Trial Phase Trials
Phase 3 4
Phase 2 16
Phase 1/Phase 2 4
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Duvelisib
Clinical Trial Phase Trials
Recruiting 15
Completed 9
Terminated 4
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Duvelisib

Sponsor Name

Sponsor Name for Duvelisib
Sponsor Trials
SecuraBio 20
Infinity Pharmaceuticals, Inc. 17
Verastem, Inc. 7
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Duvelisib
Sponsor Trials
Industry 54
Other 22
NIH 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Harvard Business School
Moodys
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.